Treatment of drug-resistant tuberculosis

Infection and Drug Resistance

Volumn 4, Issue 1, 2011, Pages 129-135

  Pinto, Lancelot ^a   Menzies, Dick ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Drug resistant tuberculosis; MDR TB; Treatment

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANAMNESIS; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; DRUG RESISTANT TUBERCULOSIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOTHYROIDISM; INSOMNIA; LIVER TOXICITY; LUPUS LIKE SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NONHUMAN; OPTIC NEURITIS; OTOTOXICITY; PATHOGENESIS; PATIENT CARE; PATIENT IDENTIFICATION; PERSONALIZED MEDICINE; QT PROLONGATION; RASH; TENDON RUPTURE; TREATMENT DURATION; TREATMENT OUTCOME; TREMOR; VESTIBULAR DISORDER;

EID: 84860474118     PISSN: 11786973     EISSN: None     Source Type: Journal    
DOI: 10.2147/IDR.S10332     Document Type: Article

References (28)

1. Treatment of tuberculosis: guidelines - 4th ed. WHO/HTM/TB/2009. 420
2. World Health Organization. Anti-tuberculosis drug resistance in the world report no. 4. WHO/HTM/TB/2008.394
3. Mak A, Thomas A, Del Granado M, Zaleskis R, Mouzafarova N, Menzies D. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med. 2008;178(3):306-312.
4. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368(9547): 1575-1580.
5. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med. 2008;359(6): 563-574.
6. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914
7. Orenstein EW, Basu S, Shah NS, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9(3):153-161.
8. Akcakir Y. Correlates of treatment outcomes of Multidrug-Resistant Tuberculosis (MDR-TB): a systematic review and meta-analysis. Montreal, QC: McGill University; 2009
9. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3
10. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000150
11. Swaminathan S, Narendran G, Venkatesan P, et al. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. Am J Respir Crit Care Med. 2010;181(7):743-751.
12. David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20(5):810-814.
13. Espinal M. What is the "fall and rise" phenomenon and the "sequential regimen" mechanism? In: Frieden T, editor. Toman's tuberculosis: case detection, treatment, and monitoring - questions and answers. 2nd ed. Geneva, Switzerland: World Health Organization; 2004:200-202.
14. Canetti G. The tubercle bacillus in pulmonary lesion of man; histobacteriology and its bearing on the therapy of pulmonary tuberculosis. New York: Springer; 1955
15. Crofton J, Mitchison DA. Streptomycin resistance in pulmonary tuberculosis. Br Med J. 1948;2(4588):1009-1015.
16. Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and metaanalysis. Ann Intern Med. 2008;149(2):123-134.
17. Udwadia ZF, Pinto LM, Uplekar MW. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades? PLoS One. 2010;5(8):e12023
18. Paydar A, Mak A, Al Jahdali H, et al. Global survey of national tuberculosis drug policies. IntJ Tuberc Lung Dis. 2011;15:613-619.
19. Becerra MC, Appleton SC, Franke MF, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet. 2011; 377(9760):147-152.
20. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):387-394.
21. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000146
22. WHO. Global tuberculosis control. Geneva, Switzerland: World Health Organization, 2010. Available at: http://whqlibdoc.who.int/publications/2010/9789241564069_eng.pdf. Accessed March 28, 2010
23. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402
24. Oxlade O, Schwartzman K, Pai M, et al. Predicting outcomes and drug resistance with standardised treatment of active tuberculosis. Eur Respir J. 2010;36(4):870-877.
25. Dorman SE, Johnson JL, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009;180(3):273-280.
26. Albalak R. A randomized trial of moxifloxacin replacing isoniazid in the intensive phase of tuberculosis (TB) treatment at a new TB research center in Russia. IUATLD-NAR 15th Annual Conference. Vancouver, BC; 2011
27. Anti-tuberculosis Drug Resistance in the World. Geneva, Switzerland: World Health Organization; 1997. WHO/ IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1994-1997. WHO_TB_97.229.
28. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency Update. WHO/ HTM/TB/2008.402.